Literature DB >> 22863560

Serum CA-125: biomarker of pulmonary tuberculosis activity and evaluation of response to treatment.

Füsun Sahin1, Pinar Yildiz.   

Abstract

PURPOSE: CA-125 is a high molecular weight mucin-like glycoprotein and an ovarian cancer antigen. Elevated CA-125 levels are also seen with various other benign and malignant conditions. In this study, the ability of CA-125 to predict pulmonary tuberculosis activity was investigated.
METHODS: This analytical study included 42 cases with active tuberculosis (Group 1), 35 cases with inactive tuberculosis (Group 2) and 20 healthy subjects (Group 3). CA-125 measurements were taken in all three groups. Measurements in Group 1 were repeated after completing a two month anti-tuberculosis treatment in 38 of the 42 patients.
RESULTS: Mean serum CA-125 level for Group 1 was 76.48 ± 24.71 U/mL, which was significantly higher than levels in Group 2 (20.01 ± 7.89 U/mL) and Group 3 (18.32 ± 2.87 U/mL) (p < 0.001). Of the 38 patients in Group 1 who were studied both pre- and post-treatment, CA-125 levels decreased significantly: from 78.88 ± 24.72 U/mL before treatment to 22.78 ± 8.02 U/mL after treatment (p < 0.001). There was no statistically significant difference between the post-treatment values of Group 1 and either Group 2 and Group 3 values (p > 0.05). Group 2 and Group 3 levels were not significantly different (p > 0.05). The cut-off level for accurate determination of activity was 36.35 U/mL. The sensitivity at this level was 97.6% and specificity was 100%.
CONCLUSION: Our findings suggest that CA-125 can be a beneficial parameter in determination of pulmonary tuberculosis activity and the evaluation of response to treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863560

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  5 in total

1.  Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Authors:  Payam Nahid; Erin Bliven-Sizemore; Leah G Jarlsberg; Mary A De Groote; John L Johnson; Grace Muzanyi; Melissa Engle; Marc Weiner; Nebojsa Janjic; David G Sterling; Urs A Ochsner
Journal:  Tuberculosis (Edinb)       Date:  2014-02-07       Impact factor: 3.131

2.  Biomarkers That Correlate with Active Pulmonary Tuberculosis Treatment Response: a Systematic Review and Meta-analysis.

Authors:  Claudia M Denkinger; Mikashmi Kohli; Alexandra J Zimmer; Federica Lainati; Nathaly Aguilera Vasquez; Carole Chedid; Sean McGrath; Andrea Benedetti; Emily MacLean; Morten Ruhwald
Journal:  J Clin Microbiol       Date:  2021-12-15       Impact factor: 5.948

3.  Identification potential biomarkers in pulmonary tuberculosis and latent infection based on bioinformatics analysis.

Authors:  Xue-Bing Qin; Wei-Jue Zhang; Lin Zou; Pei-Jia Huang; Bao-Jun Sun
Journal:  BMC Infect Dis       Date:  2016-09-21       Impact factor: 3.090

4.  Transient rise in CA 125 in a woman with ovarian carcinoma and COVID-19 infection.

Authors:  Maria Smith; Olivia D Lara; Bhavana Pothuri
Journal:  Gynecol Oncol Rep       Date:  2020-09-17

5.  Identification of Potential Biomarkers and Related Transcription Factors in Peripheral Blood of Tuberculosis Patients.

Authors:  Longxiang Xie; Xiaoyu Chao; Tieshan Teng; Qiming Li; Jianping Xie
Journal:  Int J Environ Res Public Health       Date:  2020-09-24       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.